Posted by Michael Wonder on 07 Jul 2022
US FDA awards rare paediatric disease designation to paxalisib for AT/RT, a rare form of childhood brain cancer
6 July 2022 - Kazia Therapeutics is pleased to announce that the U.S. FDA has awarded rare paediatric disease designation to Kazia’s paxalisib for the treatment of atypical rhabdoid/teratoid tumours, a rare and highly-aggressive childhood brain cancer.
Paxalisib was previously granted orphan drug designation for atypical rhabdoid/teratoid tumours by FDA on 16 June 2022.
